Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
暂无分享，去创建一个
I. Pavord | H. Ortega | S. Gupta | B. Hargadon | C. Brightling | P. Bradding | A. Wardlaw | R. Green | W. Monteiro | P. Haldar | A. Singapuri
[1] Ian D Pavord,et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.
[2] Ana Sousa,et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.
[3] Yoshiyuki Yamada,et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. , 2008, The Journal of allergy and clinical immunology.
[4] E. Israel,et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. , 2005, The Journal of allergy and clinical immunology.
[5] T. Haverty,et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. , 2004, The Journal of allergy and clinical immunology.
[6] C. Jenkins,et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. , 2001, American journal of respiratory and critical care medicine.
[7] P. Barnes,et al. Changes in sputum eosinophils predict loss of asthma control. , 2000, American journal of respiratory and critical care medicine.
[8] I. Pavord,et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. , 1999, The European respiratory journal.